Gerber Kawasaki 财富与投资管理公司减少了其在硕腾公司（Zoetis Inc. $ZTS）的股票持有量

Gerber Kawasaki Wealth & Investment Management reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 56.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,978 shares of the company's stock after selling 6,366 shares during the period. Gerber Kawasaki Wealth & Investment Management's holdings in Zoetis were worth $820,000 as of its most recent SEC filing.

• Which Pet Stock Should Get Your Tail Wagging in 2024?

Several other hedge funds also recently added to or reduced their stakes in the stock. Lansforsakringar Fondforvaltning AB publ increased its stake in Zoetis by 1.1% in the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 354,825 shares of the company's stock valued at $58,422,000 after purchasing an additional 3,853 shares during the last quarter. Oarsman Capital Inc. increased its stake in Zoetis by 7.4% in the first quarter. Oarsman Capital Inc. now owns 1,913 shares of the company's stock valued at $315,000 after purchasing an additional 132 shares during the last quarter. Cape ANN Savings Bank increased its stake in Zoetis by 7.3% in the first quarter. Cape ANN Savings Bank now owns 5,040 shares of the company's stock valued at $830,000 after purchasing an additional 341 shares during the last quarter. Guggenheim Capital LLC increased its stake in Zoetis by 11.0% in the first quarter. Guggenheim Capital LLC now owns 269,436 shares of the company's stock valued at $44,363,000 after purchasing an additional 26,675 shares during the last quarter. Finally, CreativeOne Wealth LLC increased its stake in Zoetis by 9.0% in the first quarter. CreativeOne Wealth LLC now owns 16,053 shares of the company's stock valued at $2,643,000 after purchasing an additional 1,321 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.18% of the stock is currently owned by company insiders.

Zoetis Stock Performance

• MarketBeat Week in Review – 07/31 - 08/04

NYSE:ZTS opened at $154.79 on Friday. The firm's fifty day moving average price is $153.52 and its 200 day moving average price is $158.14. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $68.60 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the firm posted $1.56 EPS. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

• Rising Dividend Make Zoetis a Doggone Winner

ZTS has been the topic of a number of research reports. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $202.43.

Check Out Our Latest Research Report on Zoetis

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

• Five stocks we like better than Zoetis
• High Flyers: 3 Natural Gas Stocks for March 2022
• Snowflake’s Snowballing Business and Robust Stock Price Outlook
• The Top 3 Healthcare Dividend Stocks to Buy and Hold
• Chevron Stock Outlook: Dividend Growth Meets Inflation
• When to Sell a Stock for Profit or Loss
• Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zoetis Right Now?

Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here